Diyabet çağımızın salgın hastalığı olarak kabul
edilmekte ve tüm dünyada prevalansı hızla artmaktadır. Diyabet pek çok
hastalığın ve olumsuz durumun gelişmesinde yatkınlık oluşturmaktadır. Diyabetik retinopati orta ve ileri yaşta görme
azlığı yapan en önemli nedenlerdendir; gelişmiş ülkelerde 3’üncü körlük
nedenidir. Ancak diyabetik retinopati dışında da yavaş gelişen görme kaybının birçok nedeni vardır. Yavaş
gelişen görme kayıpları en sık katarakt, göz kusurları, şeker hastalığı, yaşa
bağlı sarı nokta hastalığı gibi durumlara bağlıdır. Göz tansiyonunun ani
yükselmesi, göz enfeksiyonu gibi durumlar da ağrı ile birlikte kalıcı görme
kaybına yol açabilir. Birçok nörolojik
hastalıkta da görme ile ilgili yakınmalar ortaya çıkabilmektedir. Bunlar
arasında optik nörit, göz siniri damarının tıkanması, göz siniri tümörleri,
hipofiz bezi tümörleri, beyin damar tıkanıklıkları ve genetik hastalıklar gibi
nedenler vardır. Endokrinoloji polikliniğimize
diyabet takibi için başvuran 5 yıldır tam görme kaybı olan ancak tetkiklerinde
dev suprasellar kitle tespit edilen ve sonrasında menenjiom tanısı koyduğumuz
olguyu sunuyoruz.
Diabetes is
considered an epidemic of our age and the prevalence of the whole world is rapidly increasing.
Diabetes is predisposing to the development of many diseases and adverse
events. Diabetic retinopathy is the most important cause of blindness in middle
and advanced age; is the third cause of blindness in developed countries.
However, there are many reasons for slow vision loss other than diabetic
retinopathy. Slow-developing visual loss is most often due to cataracts, eye
defects, diabetes, age-related yellow spot disease. Sudden elevation of eye
pressure, such as eye infection, can also cause permanent visual loss with
pain. In many neurological diseases, complaints about vision can occur. These
include optic neuritis, blockage of the optic nerve, ocular neural tumors,
pituitary gland tumors, cerebral vascular occlusions and genetic diseases. We
present to our endocrinology outpatient clinic a case of complete loss of
vision for 5 years, but a giant suprasellar mass is detected in the examination
and a diagnosis of menengioma after that.
Primary Language | English |
---|---|
Subjects | Health Care Administration |
Journal Section | Case Report |
Authors | |
Publication Date | January 15, 2020 |
Published in Issue | Year 2020 Volume: 3 Issue: 1 |
Interuniversity Board (UAK) Equivalency: Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS].
The Directories (indexes) and Platforms we are included in are at the bottom of the page.
Note: Our journal is not WOS indexed and therefore is not classified as Q.
You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/2316/file/4905/show
The indexes of the journal are ULAKBİM TR Dizin, Index Copernicus, ICI World of Journals, DOAJ, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, WorldCat (OCLC), MIAR, EuroPub, OpenAIRE, Türkiye Citation Index, Türk Medline Index, InfoBase Index, Scilit, etc.
The platforms of the journal are Google Scholar, CrossRef (DOI), ResearchBib, Open Access, COPE, ICMJE, NCBI, ORCID, Creative Commons, etc.
Our Journal using the DergiPark system indexed are;
Ulakbim TR Dizin, Index Copernicus, ICI World of Journals, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, OpenAIRE, MIAR, EuroPub, WorldCat (OCLC), DOAJ, Türkiye Citation Index, Türk Medline Index, InfoBase Index
Our Journal using the DergiPark system platforms are;
Journal articles are evaluated as "Double-Blind Peer Review".
Our journal has adopted the Open Access Policy and articles in JHSM are Open Access and fully comply with Open Access instructions. All articles in the system can be accessed and read without a journal user. https//dergipark.org.tr/tr/pub/jhsm/page/9535
Journal charge policy https://dergipark.org.tr/tr/pub/jhsm/page/10912
Editor List for 2022
Assoc. Prof. Alpaslan TANOĞLU (MD)
Prof. Aydın ÇİFCİ (MD)
Prof. İbrahim Celalaettin HAZNEDAROĞLU (MD)
Prof. Murat KEKİLLİ (MD)
Prof. Yavuz BEYAZIT (MD)
Prof. Ekrem ÜNAL (MD)
Prof. Ahmet EKEN (MD)
Assoc. Prof. Ercan YUVANÇ (MD)
Assoc. Prof. Bekir UÇAN (MD)
Assoc. Prof. Mehmet Sinan DAL (MD)
Our journal has been indexed in DOAJ as of May 18, 2020.
Our journal has been indexed in TR-Dizin as of March 12, 2021.
Articles published in the Journal of Health Sciences and Medicine have open access and are licensed under the Creative Commons CC BY-NC-ND 4.0 International License.